Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
Phase 1/2 Completed
51 enrolled 13 charts
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
Phase 2 Completed
122 enrolled 22 charts
GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu
Phase 1 Completed
13 enrolled
Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer
Phase 2 Completed
30 enrolled 6 charts
Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer
Phase 2 Completed
63 enrolled 8 charts
Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer
Phase 2 Completed
20 enrolled 6 charts
Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
Phase 1 Completed
9 enrolled
Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer
Phase 1/2 Completed
30 enrolled 13 charts
Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
Phase 2 Completed
95 enrolled 7 charts
Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer
Phase 2 Completed
47 enrolled 8 charts
Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer
Phase 1/2 Completed
31 enrolled 10 charts
Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
Phase 2 Completed
32 enrolled 6 charts
Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Phase 2 Terminated
6 enrolled 8 charts
T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors
Phase NA Completed
12 enrolled
Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer
Phase 2 Withdrawn